Is atherosclerosis accelerated in systemic sclerosis? Novel insights

Current Opinion in Rheumatology

Volumn 26, Issue 6, 2014, Pages 653-657

  Soriano, Alessandra ^a,b   Afeltra, Antonella ^a   Shoenfeld, Yehuda ^b,c  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Atherosclerosis; Cardiovascular disease; Systemic sclerosis

Indexed keywords

N(G),N(G) DIMETHYLARGININE; PHOSPHOLIPID ANTIBODY;

ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CORONARY FLOW RESERVE; DISEASE EXACERBATION; HEART DISEASE; HUMAN; ISCHEMIC HEART DISEASE; MICROANGIOPATHY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STRESS ECHOCARDIOGRAPHY; SYSTEMIC SCLEROSIS; COMPLICATION; DISEASE COURSE; PATHOLOGY; RISK FACTOR;

ATHEROSCLEROSIS; CAROTID INTIMA-MEDIA THICKNESS; DISEASE PROGRESSION; HUMANS; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 84927741122     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000115     Document Type: Review

References (32)

1. Bichile T, Petri M. Prevention and management of co-morbidities in SLE. Press Med 2014; 43:e187-e195.
2. Choy E, Ganeshalingam K, Semb AG, et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 2014. [Epub ahead of print]
3. Dave AJ, Fiorentino D, Lingala B, et al. Atherosclerotic cardiovascular disease in hospitalized patients with systemic sclerosis: higher mortality than patients with lupus and rheumatoid arthritis. Arthritis Care Res 2014; 66:323-327.
4. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69:1809-1815.
5. Ngian GS, Sahhar J, Wicks IP, Van Doornum S. Cardiovascular disease in systemic sclerosis-an emerging association? Arthritis Res Ther 2011; 13:237.
6. Akamata K, Asano Y, Aozasa N, et al. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1. Arthritis Res Ther 2014; 16:R86.
7. Makino K, Jinnin M, Aoi J, et al. Knockout of endothelial cell-derived endothelin-1 attenuates skin fibrosis but accelerates cutaneous wound healing. PLoS One 2014; 9:e97972.
8. Li MW, Mian MO, Barhoumi T, et al. Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 2013; 33:2306-2315.
9. Derrett-Smith EC, Dooley A, Gilbane AJ, et al. Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma indices pulmonary hypertension. Arthritis Rheum 2013; 65:2928-2939.
10. Gistera A, Robertson AK, Andersson J, et al. Transforming growth factor-b signalling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci Transl Med 2013; 5:196ra100.
11. Majka DS, Liu K, Pope RM, et al. Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort. Inflamm Res 2013; 62:919-927.
12. Boin S, Franchini S, Colantuoni E, et al. Independent association of antibeta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients. Arthritis Rheum 2009; 60:2480-2489.
13. Morrisroe KB, Stevens W, Nondurkar H, et al. The association of antiphospholipid antibodies with cardiopulmonary manifestations of systemic sclerosis. Clin Exp Rheumatol 2014. [Epub ahead of print]
14. Man A, Zhu Y, Zhang Y, et al. The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Ann Rheum Dis 2013; 72:1188-1193.
15. Ngian GS, Joanne S, Proudman SM, et al. Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. Ann Rheum Dis 2012; 71:1980-1983.
16. Au K, Singh MK, Bodukam V, et al. Atherosclerosis in systemic sclerosis. A systematic review and meta-analysis. Arthritis Rheum 2011; 63:2078-2090.
17. Sanna G, Bertolaccini ML, Mameli A, et al. Antiphospholipid antibodies in patients with scleroderma: prevalence and clinical significance. Ann Rheum Dis 2005; 64:1795-1796.
18. Marie I, Jouen F, Hellot MF, et al. Anticardiolipin and antibeta2 glycoprotein I antibodies and lupus anticoagulant: prevalence and significance in systemic sclerosis. Br J Dermatol 2008; 158:141-144.
19. Mok MY, Lau CS, Chiu SS, et al. Systemic sclerosis is an independent factor for increased coronary artery calcium deposition. Arthritis Rheum 2011; 63:1387-1395.
20. Chu SY, Chen JY, Liu CJ, et al. Increased risk of acute myocardial infarction in systemic sclerosis: a nationwide population-based study. Am J Med 2013; 126:982-988.
21. Nordin A, Jensen-Urstad K, Biornadal L, et al. Ischemic arterial events and atherosclerosis in patients with systemic sclerosis: a population-based casecontrol study. Arthritis Res Ther 2013; 15:R87.
22. Nussinovitch U, Shoenfeld Y. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev 2011; 10:259-266.
23. Zeng Y, Li M, Xu D, et al. Macrovascular involvement in systemic sclerosis: evidence of correlation with disease activity. Clin Exp Rheumatol 2014; 30 (Suppl 71):S76-S80.
24. Hettema ME, Zhang D, de Leeuw K, et al. Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthitis Res Ther 2008; 10:R49.
25. Akram MR, Handler CE, Williams M, et al. Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford) 2006; 45:1395-1398.
26. Turiel M, Gianturco L, Ricci C, et al. Silent cardiovascular involvement in patients with diffuse systemic sclerosis: a controlled cross-sectional study. Arthritis Care Res 2013; 65:274-280.
27. Atzeni F, Sarzi-Puttini P, Sitia S, et al. Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patient with psoriatic arthritis. J Rheumatol 2011; 38:1661-1664.
28. Turiel M, Atzeni F, Tomasoni L, et al. Noninvasive assessment of coronary flow reserve and ADMA levels: a case control study of early rheumatoid arthritis patients. Rheumatology (Oxford) 2009; 48:834-839.
29. McKay ND, Griffiths B, Di Maria C, et al. Novel photoplethysmography cardiovascular assessments in patients with Raynaud's phenomenon and systemic sclerosis: a pilot study. Rheumatology (Oxford) 2014. [Epub ahead of print]
30. Frerix M, Stegbauer J, Kreuter A, Weiner SM. Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and lupus erythematosus: a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events. Arthritis Res Ther 2014; 16:R54.
31. Sano M, Satoh H, Suka W, et al. Characteristic and clinical relevance of late gadolinium enhancement in cardiac magnetic resonance in patients with systemic sclerosis. Heart Vessels 2014. [Epub ahead of print]
32. Webber M, Natarajan A, Schreiber B, et al. Cardiac involvement in systemic sclerosis: strengths and limitations of cardiac magnetic resonance imaging. Heart 2014; 100 (Suppl 3):A80.